Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | A Phase I/II trial of seclidemstat in combination with azacitidine for patients with MDS and CMML

Guillermo Montalban-Bravo • 15 Jun 2024
EHA 2024
Chronic Myelomonocytic Leukemia Leukemia Myelodysplastic Syndromes Rare Diseases Azacitidine Seclidemstat

Guillermo Montalban-Bravo, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a Phase I/II study on seclidemstat combined with azacitidine for myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). The trial is concluding the dose-escalation phase, showing promising activity and good safety, but further dose expansion is needed to draw conclusions. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Guillermo Montalban-Bravo

1:18
Targeting MCL1-mediated survival to overcome HMA resistance in CMML
Guillermo Montalban-Bravo • 15 Jun 2024

Related Videos

0:43
Reducing chemotherapy-induced adverse events in patients with AML
Fabio Guolo • 16 Jun 2024
3:24
Pre-induction azacitidine and venetoclax to improve the bone marrow microenvironment in AML
Maher Salamoon • 26 Jun 2024
4:41
Intrathecal rituximab plus dexamethasone in B-cell malignancies with CNS involvement
Maher Salamoon • 26 Jun 2024
4:31
The impact of high and low burden TP53 mutations on risk and treatment decision in CLL
Maher Salamoon • 26 Jun 2024
The content of VJHemOnc is intended for healthcare professionals